IMMUNOGENICITY OF THERAPEUTIC FUSION PROTEINS: CONTRIBUTORY FACTORS AND CLINICAL EXPERIENCE - Fusion Protein Technologies for Biopharmaceuticals: Applications and Challenges - page 86

52. Koren E, De Groot AS, Jawa V, Beck KD, Boone T, Rivera D,
et al. (2007) Clinical validation of the “in silico” prediction of
immunogenicity of a human recombinant therapeutic protein.
Clin. Immunol. 124, 26-32.
53. Baker MP, Jones TD. (2007) Identification and removal of
immunogenicity in therapeutic proteins. Curr. Opin. Drug
Discov. Devel. 10, 219-227.
54. Wullner D, Zhou L, Bramhall E, Kuck A, Goletz TJ, Swanson
S, et al. (2010) Considerations for optimization and validation
of an in vitro PBMC derived T cell assay for immunogenicity
prediction of biotherapeutics. Clin. Immunol. 137, 5-14.
55. Steere AC, Klitz W, Drouin EE, Falk BA, Kwok WW, Nepom
GT, et al. (2006) Antibiotic-refractory Lyme arthritis is asso-
ciated with HLA-DR molecules that bind a Borrelia burgdor-
feri peptide. J. Exp. Med. 203, 961-971.
56. McMurry JA, Kimball S, Lee JH, Rivera D, Martin W, Weiner
DB, et al. (2007) Epitope-driven TB vaccine development: a
streamlined approach using immuno-informatics, ELISpot
assays, and HLA transgenic mice. Curr. Mol. Med. 7, 351-368.
57. Jaber A, Baker M. (2007) Assessment of the immunogenicity
of different interferon beta-1a formulations using ex vivo
T-cell assays. J. Pharm. Biomed. Anal. 43, 1256-1261.
58. Vossen MT, Westerhout EM, Soderberg-Naucler C, Wiertz EJ.
(2002) Viral immune evasion: a masterpiece of evolution.
Immunogenetics 54, 527-542.
59. De Groot AS, Knopp PM, Martin W. (2005) De-immunization
of therapeutic proteins by T-cell epitope modification. Dev.
Biol. (Basel) 122, 171-194.
60. Podojil JR, Turley DM, Miller SD. (2008) Therapeutic block-
ade of T-cell antigen receptor signal transduction and costi-
mulation in autoimmune disease. Adv. Exp. Med. Biol. 640,
234-251.
61. Tsuji NM, Kosaka A. (2008) Oral tolerance: intestinal
homeostasis and antigen-specific regulatory T cells. Trends
Immunol. 29, 532-540.
62. Chatenoud L, Bluestone JA. (2007) CD3-specific antibodies: a
portal to the treatment of autoimmunity. Nat. Rev. Immunol. 7,
622-632.
63. Alegre ML, Fallarino F. (2006) Mechanisms of CTLA-4-Ig in
tolerance induction. Curr. Pharm. Des. 12, 149-160.
64. Pechhold K, Koczwara K. (2008) Immunomodulation of auto-
immune diabetes by dendritic cells. Curr. Diab. Rep. 8, 107-113.
65. Skupsky J, Su Y, Lei TC, Scott DW. (2007) Tolerance
induction by gene transfer

hematopoietic progenitors or peripheral B lymphocytes.
Mol. Med. 3, 212-224.
69. Soukhareva N, Jiang Y, Scott DW. (2006) Treatment of diabe-
tes in NOD mice by gene transfer of Ig-fusion proteins into B
cells: role of T regulatory cells. Cell Immunol. 240, 41-46.
70. De Groot AS, Moise L, McMurry JA, Wambre E, Van Over-
tvelt L, Moingeon P, et al. (2008) Activation of natural
regulatory T cells by IgG Fc-derived peptide “Tregitopes”.
Blood 112, 3303-3311.
71. Maddur MS, Othy S, Hegde P, Vani J, Lacroix-Desmazes S,
Bayry J, et al. (2010) Immunomodulation by intravenous
immunoglobulin: role of regulatory T cells. J. Clin. Immunol.
30(Suppl. 1), S4-S8.
72. Ephrem A, Chamat S, Miquel C, Fisson S, Mouthon L,
Caligiuri G, et al. (2008) Expansion of CD4 þ CD25 þ regula-
tory T cells by intravenous immunoglobulin: a critical factor in
controlling experimental

autoimmune encephalomyelitis.

Blood 111, 715-722.
73. Kaveri S, Prasad N, Vassilev T, Hurez V, Pashov A, Lacroix-
Desmazes S, et al. (1997) Modulation of autoimmune responses
by intravenous immunoglobulin (IVIg). Mult. Scler. 3, 121-128.
74. Lopez M, Clarkson MR, Albin M, Sayegh MH, Najafian N.
(2006) A novel mechanism of action for anti-thymocyte
globulin:

induction of CD4 þ CD25 þ Foxp3 þ regulatory T

cells. J. Am. Soc. Nephrol. 17, 2844-2853.
75. De Groot AS. (2008) IgG Tregitopes and AITD-ASATI: anti-
gen specific tolerance induction in autoimmune thyroid
disease. Tregs and Th17 Cells in Autoimmunity, Washington,
DC.
76. De Groot AS, Moise L, Li X, Su Y, Yang W, Desrosiers J, et al.
(2009) Effect of Tregitopes on T1D Immune response in vitro
and on diabetes in NOD mice. 2nd European Congress of
Immunology, Berlin, Germany.
77. D'Addio F, Boenisch O, Wattanabe T, De Groot AS, Sayegh
MH, Najafian N. (2009) Immuno-modulatory functions of a
novel IgG Fc-derived peptides, Tregitopes, in alloimmunity.
American Transplant Conference, Boston, MA.
78. Su Y, Moise L, Li X, Rossi R, Skupsky J, Martin WD, et al.
(2009) T cell epitopes (Tregitopes) contained in IgG constant
domains activate natural Tregs. 1st International Conference
on Tolerance, Elsevier, Boston, MA.
79. Mingozzi F, Finn JD, Zhou S, Hui DJ, Pien GC, Basner-
Tschakarjan E, et al. (2009) Suppression of CTL responses
against AAV-capsid epitopes by peptide-induced regulatory T
cells. American Society for Hematology, Oral Session: Gene
Therapy and Transfer, New Orleans, LA.
80. Buhlmann JE, Najafian N, Hui DJ, D'Addio F, Mingozzi F,
Moise L, et al. (2010) Preclinical design of less immunogenic
biologics: tregitopes and tolerance. Annual Meeting of the
American Association of Immunologists, Baltimore, MD.
81. De Groot AS, Najafian N, Hui DJ, D'Addio F, Mingozzi F,
Moise L, et al. (2010) Preclinical design of less immunogenic
biologics: tregitopes and tolerance. AAPS 2010 National
Biotechnology Conference, San Francisco, CA.
82. Sharabi A, Lapter S, Mozes E. (2010) Bcl-xL is required for
the development of functional regulatory CD4 cells in lupus-

to lymphocytes. Curr. Gene

Ther. 7, 369-380.
66. Borel Y, Borel H. (1988) Oligonucleotide linked to human
gammaglobulin specifically diminishes anti-DNA antibody
formation in cultured lymphoid cells from patients with sys-
temic lupus erythematosus. J. Clin. Invest. 82, 1901-1907.
67. Zambidis ET, Scott DW. (1996) Epitope-specific tolerance
induction with an engineered immunoglobulin. Proc. Natl.
Acad. Sci. USA 93, 5019-5024.
68. Zambidis ET, Kurup A, Scott DW. (1997) Genetically trans-
ferred central and peripheral immune tolerance via retroviral-
mediated expression of immunogenic epitopes in